Clinical trial NCT02196558: A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
Official title: A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Arthritis, Rheumatoid
Keywords: Rheumatoid Arthritis
Japanese subjects
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2014-07-22
Enrollment: 53
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study consist of treatment phase (12 weeks) and extension phase (40 weeks). This study is a multicenter, open-label, uncontrolled, multiple ascending dose (MAD) study to evaluate mainly the safety and tolerability of 12-week repeated subcutaneous administration of E6011 in Japanese subjects with Rheumatoid Arthritis. First 12 subjects will enroll as 100 mg group, next 12 subjects will enroll as 200 mg group, and last 9 subjects will enroll as 400 mg group. A total of 33 subjects will receive repeated subcutaneous administration of E6011. Subjects who roll over onto the Extension phase will have continued monitoring until 52 weeks after the initial administration.


Eligibility criteria: Inclusion Criteria

Subjects must meet all of the following criteria to be included in this study:

1. Japanese patients aged 20 to 64 years old at the time of informed consent.
2. Diagnosed with rheumatoid arthritis (RA) who meet the 1987 ACR or 2010 ACR/EULAR criteria.
3. Presenting tenderness in more than 4 joints (out of 68) and swelling in more than 4 joints (out of 66) at Screening and Observation phase.
4. Never been treated with non-anti-TNF biologics or never been treated with 2 or more anti-TNF agents.
5. Subjects with greater than or equal to 0.6 mg/dL of high-sensitivity CRP (hs-CRP) level or greater than or equal to 28 mm/hr of erythrocyte sedimentation rate (ESR) at Screening.
6. Weighs greater than or equal to 30 kg and less than or equal to 100 kg at Screening.
7. Consent to use contraception (both the subject and the subject's partner), for at least 70 days after the last dose of study medication starting on the day of informed consent, if the subject is a man capable of reproduction or a woman of childbearing potential.
8. Has voluntarily consented, in writing, to participate in this study
9. Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with all aspects of the protocol.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

1. Any history or complication of inflammatory arthritic disorder other than rheumatoid arthritis or Sjogren's syndrome.
2. Meet Class 4 with the Steinbrocker functional classification.
3. History or current clinical condition, or associated complications of malignant tumor, lymphoma, leukemia, or lymphoproliferative disease.
4. Immunodeficiency or history of HIV infection
5. Infection requiring hospitalization or intravenous administration of antibiotics within 4 weeks before the first dose of study treatment, or an infection requiring oral antibiotics within 2 weeks before the first dose of study treatment.
6. History of tuberculosis or current complication of active tuberculosis.
7. History of severe allergy (shock, or anaphylactoid symptoms).
8. History of clinically important vascular edema, hematemesis, hemorrhagic stool, or hemoptysis.
9. History of acute myocardial infarction, cerebral infarction, cerebral hemorrhage, or arteriosclerosis obliterans.
10. History of clinically important vasculitis (such as mononeuritis multiplex).
11. Tested positive for any of the following at Screening: human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs antibody), hepatitis B virus core antibody (HBc antibody), hepatitis B virus DNA (HBV DNA), hepatitis C virus antibody (HCV antibody), human T-lymphotrophic virus Type I antibody (HTLV-1 antibody), or syphilis.
12. Any result other than negative in tuberculosis test (T-SPOT.TB Test or QuantiFERON TB Gold Test) at Screening.
13. Findings indicating a history of tuberculosis on chest X-ray at Screening.
14. Ineligible to participate in the study in the opinion of the investigator or sub investigator.

Primary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
timeFrame: Up to 52 Weeks
Secondary outcomes:
measure: Number of Participants With Positive Anti-E6011 Antibodies Results
timeFrame: Up to 52 weeks
measure: Serum Concentrations of E6011
timeFrame: At Week 0 (predose), Week 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (postdose)
Other outcomes:
Locations:
city: Kitakyushu
country: Japan
state: Fukuoka
city: Sapporo
country: Japan
state: Hokkaido
city: Kakogawa
country: Japan
state: Hyogo
city: Kato
country: Japan
state: Hyogo
city: Kahoku-gun
country: Japan
state: Ishikawa
city: Yokohama
country: Japan
state: Kanagawa
city: Hamamatsu
country: Japan
state: Shizuoka
city: Chuo-Ku
country: Japan
state: Tokyo
city: Meguro-Ku
country: Japan
state: Tokyo
city: Ota-Ku
country: Japan
state: Tokyo
city: Shinjuku-Ku
country: Japan
state: Tokyo
city: Miyazaki
country: Japan
Study officials:
References:
citation: Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, Imai T. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 2018 Jan;28(1):58-65. doi: 10.1080/14397595.2017.1337056. Epub 2017 Jul 6.